000117216 001__ 117216
000117216 005__ 20230519145553.0
000117216 0247_ $$2doi$$a10.1016/j.vaccine.2021.06.049
000117216 0248_ $$2sideral$$a126758
000117216 037__ $$aART-2021-126758
000117216 041__ $$aeng
000117216 100__ $$0(orcid)0000-0003-2993-5478$$aMartín, C.$$uUniversidad de Zaragoza
000117216 245__ $$aMTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG
000117216 260__ $$c2021
000117216 5060_ $$aAccess copy available to the general public$$fUnrestricted
000117216 5203_ $$aAt its 100th birthday of its first administration to a newborn, BCG has been (and continues being) an inspiration for the construction and development of hundreds of new TB vaccine candidates in the last two and a half decades. Today, 14 candidates are in clinical development inside the global TB vaccine pipeline. MTBVAC is one of these candidates. Based on a live-attenuated Mycobacterium tuberculosis clinical isolate, MTBVAC''s 25 years of vaccine discovery, construction and characterisation have followed Pasteur principles, and in the process, BCG has served as a reference gold standard for establishing the safety and protective efficacy of new TB vaccine candidates. MTBVAC, which contains the antigen repertoire of M. tuberculosis, is now poised to initiate Phase 3 efficacy trials in newborns in TB-endemic countries. BCG''s efficacy extends beyond that against TB, shown to confer heterologous non-specific immunity to other diseases and reduce all-cause mortality in the first months of life. Today, WHO recognises the importance that any new TB vaccine designed for administration at birth, should show similar non-specific benefits as BCG vía mechanisms of trained immunity and/or cross-reactivity of adaptive immune responses to other pathogens. Key recent studies provide strong support for MTBVAC''s ability of inducing trained immunity and conferring non-specific heterologous protection similar to BCG. Research on alternative delivery routes of MTBVAC, such as a clinically feasible aerosol route, could facilitate vaccine administration for long-term TB eradication programmes in the future. © 2021 The Author(s)
000117216 536__ $$9info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 643381-TBVAC2020$$9info:eu-repo/grantAgreement/ES/MICINN/RTC-2017-6379-1
000117216 540__ $$9info:eu-repo/semantics/openAccess$$aby-nd$$uhttp://creativecommons.org/licenses/by-nd/3.0/es/
000117216 590__ $$a4.169$$b2021
000117216 592__ $$a1.392$$b2021
000117216 594__ $$a6.7$$b2021
000117216 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b73 / 140 = 0.521$$c2021$$dQ3$$eT2
000117216 593__ $$aImmunology and Microbiology (miscellaneous)$$c2021$$dQ1
000117216 591__ $$aIMMUNOLOGY$$b94 / 163 = 0.577$$c2021$$dQ3$$eT2
000117216 593__ $$aVeterinary (miscellaneous)$$c2021$$dQ1
000117216 593__ $$aPublic Health, Environmental and Occupational Health$$c2021$$dQ1
000117216 593__ $$aInfectious Diseases$$c2021$$dQ1
000117216 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000117216 700__ $$aMarinova, D.
000117216 700__ $$0(orcid)0000-0001-7897-9173$$aAguiló, N.$$uUniversidad de Zaragoza
000117216 700__ $$0(orcid)0000-0001-8841-6593$$aGonzalo-Asensio, J.$$uUniversidad de Zaragoza
000117216 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000117216 773__ $$g39, 50 (2021), 7277-7285$$pVaccine$$tVACCINE$$x0264-410X
000117216 8564_ $$s1223458$$uhttps://zaguan.unizar.es/record/117216/files/texto_completo.pdf$$yVersión publicada
000117216 8564_ $$s2706197$$uhttps://zaguan.unizar.es/record/117216/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000117216 909CO $$ooai:zaguan.unizar.es:117216$$particulos$$pdriver
000117216 951__ $$a2023-05-18-15:52:22
000117216 980__ $$aARTICLE